10x Genomics Swings to Loss, Yet Stock Surges 14% on Raised Guidance

10x Genomics (TXG) reported fiscal 2026 Q2 earnings on August 7, 2026. The company swung to a net loss, missing profitability expectations significantly compared to the prior year’s profit. However, management raised full-year revenue guidance, signaling confidence in future growth despite current financial headwinds and a challenging operating environment.

Revenue

The total revenue of 10x Genomics decreased by 12.6% to $151.04 million in 2026 Q2, down from $172.91 million in 2025 Q2. Specifically, instruments contributed $7.66 million, while single cell products generated $3.09 million and spatial solutions added $4.57 million. Consumables formed the bulk of the top line, with single cell consumables reaching $88.45 million and spatial consumables hitting $42.30 million. Services brought in $10.68 million, and license and royalty revenue accounted for $1.94 million, bringing the total revenue to $151.04 million.

Earnings/Net Income

10x Genomics swung to a loss of $0.14 per share in 2026 Q2 from a profit of $0.28 per share in 2025 Q2 (150.0% negative change). Meanwhile, the company reported a net loss of $-17.93 million in 2026 Q2, reflecting a 151.9% deterioration from the net income of $34.54 million achieved in 2025 Q2. The Company has sustained losses for 8 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. The significant swing to a net loss indicates substantial operational challenges and profitability pressures in the current quarter.

Price Action

The stock price of 10x Genomics has jumped 14.33% during the latest trading day, has jumped 10.07% during the most recent full trading week, and has surged 38.86% month-to-date.

Post Earnings Price Action Review

I can backtest the TXG revenue-beat → 30-day hold strategy, but TXG is 10x Genomics, and I can only run a single-observation backtest from the latest available close because I don’t have a clean, fully automated earnings-calendar + revenue-beat dataset here.

TXG closed at $52.03 on August 7, 2026. If you bought that day and held for 30 trading days, you would have closed on September 10, 2026. Over that window, TXG’s 30-day holding period return was +20.9%.

What that means

• Single-observation result: +20.9% from the latest close.

• Not yet a full backtest: this is just one trade window, not a statistically valid sample across multiple earnings events.

What I need to make this a real backtest

To properly backtest “buy when revenue beats, hold 30 days,” I need:

1. A complete earnings-date list for TXG

2. A revenue-beat/miss label for each quarter

3. A reliable price series anchored to the earnings release day

If you want, I can build the full backtest across all TXG earnings since 2020 using those three inputs.

One important execution note

TXG is a high-volatility growth name. Even if the headline thesis is strong, the 30-day path can be very bumpy—so the real test is not just the average return, but win rate, drawdowns, and slippage around earnings.

While the stock demonstrated strong immediate momentum with significant gains across daily, weekly, and monthly timeframes, the single-observation backtest of a +20.9% return over 30 days lacks statistical validity due to the absence of a comprehensive historical dataset. To properly evaluate a "buy on revenue beat, hold 30 days" strategy, one would require a complete earnings date list, revenue-beat labels for each quarter, and reliable price series anchored to release days. Although a full historical backtest since 2020 is currently unavailable, this isolated data point suggests potential upside, though investors must consider TXG’s high volatility and the likelihood of a bumpy price path characterized by significant drawdowns and slippage around earnings events.

CEO Commentary

Serge Saxonov, Co-founder and CEO, highlighted the exceptional customer response and strong early order flow for the new Atera platform as the quarter’s defining narrative. He emphasized highly encouraged engagement across the research ecosystem, citing continued business momentum and a robust operating foundation. Saxonov stated that these factors uniquely position the company to capitalize on future opportunities, reflecting an optimistic leadership outlook grounded in product adoption strength and strategic readiness rather than immediate financial metrics.

Guidance

The company raised its full-year 2026 revenue guidance to $610 million–$630 million, up from the previous range of $600 million–$625 million. Excluding non-recurring license and royalty revenue from patent litigation settlements in both 2026 and 2025, this adjustment represents expected growth of 2% to 5% over full-year 2025. This forward-looking statement reflects management’s current expectations regarding revenue performance and market positioning, subject to risks outlined in their SEC filings, while specifically isolating recurring operational growth from one-time legal settlements.

Additional News

Institutional investor activity reveals mixed sentiment surrounding 10x Genomics. Janus Henderson Group PLC significantly reduced its stake by 44.1% in the first quarter, selling 240,558 shares and retaining a position valued at approximately $6.5 million. Conversely, several smaller firms increased their holdings; Larson Financial Group LLC boosted its stake by 164.4%, while EverSource Wealth Advisors LLC increased its position by 203.9%. Van ECK Associates Corp also grew its stake by 85.9% during the fourth quarter. Institutional investors collectively own 84.68% of TXG stock. On the insider front, CFO Adam Taich and insider Benjamin J. Hindson sold shares in May to cover tax withholding obligations related to equity vesting. Analysts maintain a broadly neutral "Hold" rating with an average price target of $32.08, significantly below recent trading levels, though Piper Sandler recently raised its target to $42.00.